Stocktoria
Tilray Brands, Inc. TLRY
Nasdaq · XNAS · stock · Medicinal Chemicals & Botanical Products · website · IPO 2018-07-19
Chart by TradingView
5/9
Piotroski F — financial health
-11.01
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $821.3M | $788.9M | $627.1M | $628.4M | $513.1M |
| Gross profit | $240.6M | $223.4M | $147.0M | $116.8M | $123.2M |
| Operating income | -$2.3B | -$174.7M | -$1.4B | -$610.4M | -$132.2M |
| Net income | -$2.2B | -$245.0M | -$1.5B | -$476.8M | -$367.4M |
| Operating cash flow | -$94.6M | -$30.9M | $7.9M | -$177.3M | -$44.7M |
| Total assets | $2.1B | $4.2B | $4.3B | $5.4B | $6.0B |
| Total liabilities | $584.8M | $778.5M | $977.3M | $1.0B | $1.6B |
| Shareholders' equity | $1.5B | $3.4B | $3.3B | $4.4B | $4.5B |
| Ratios | |||||
| Gross margin | 29.3% | 28.3% | 23.4% | 18.6% | 24.0% |
| Operating margin | -277.9% | -22.1% | -218.4% | -97.1% | -25.8% |
| Net margin | -266.3% | -31.1% | -231.6% | -75.9% | -71.6% |
| Return on assets | -105.4% | -5.8% | -33.7% | -8.7% | -6.1% |
| Return on equity | -144.7% | -7.1% | -43.6% | -10.7% | -8.2% |
| Debt / equity | — | — | — | 0.04× | 0.05× |
| Current ratio | 2.46 | 2.27 | 1.79 | 2.87 | 2.20 |
| Revenue growth | 4.1% | 25.8% | -0.2% | 22.5% | 143.8% |
Why these scores methodology →
Piotroski F-score: 5/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -11.01 (distress)
- Working capital / assets 0.197
- Retained earnings / assets -2.337
- EBIT / assets -1.1
- Equity / liabilities 2.585
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001731348 · as of 2025-05-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.